---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015608"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:11:22.604259+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protalix Q3 net income $3.2M, revenue up 75%; PRX-115 Phase I positive

## Summary
- Revenue from goods $17.8M (+75% YoY); net income $3.2M vs loss $1.9M in Q3 2023; EPS $0.04 basic.
- PRX-115 Phase I completed all eight cohorts; single dose lowered uric acid below 6.0 mg/dL for up to 12 weeks at highest doses.
- PRX-115 well-tolerated: 25% of treated subjects reported mild-to-moderate AEs; one resolved anaphylactic reaction.
- Cash $27.4M at Sept 30; repaid 7.5% senior secured convertible notes due Sept 2024 from available cash.
- Planning phase II trial of PRX-115 in gout patients, initiation expected H2 2025.

## SEC filing metadata
- accession: 0001558370-24-015608
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837024015608/0001558370-24-015608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837024015608/plx-20241114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015608
- JSON: https://secwatch.observer/filing/0001558370-24-015608.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.